https://orcid.org/0000-0002-5514-6459
References
- Spivak JL. Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now? Lancet Haematol. 2020;7:e184–e185.
- Nazha A, Khoury JD, Verstovsek S, et al. Second line therapies in polycythemia vera: what is the optimal strategy after hydroxyurea failure? Crit Rev Oncol Hematol. 2016;105:112–117.
- Shen XZ, Bernstein KE. The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle (Georgetown, Tex.). 2011;10:1363–1369.
- Bernstein KE, et al. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev. 2013;65:1–46.
- Jokubaitis VJ, et al. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood. 2008;111:4055–4063.
- Haznedaroğlu IC, Arici M, Büyükaşik Y. A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. Med Hypotheses. 2000;54:80–83.
- Hubert C, Savary K, Gasc JM, et al. The hematopoietic system: a new niche for the renin-angiotensin system. Nat Clin Pract Cardiovasc Med. 2006;3:80–85.
- Naito M, Kawashima A, Akiba T, et al. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol. 2003;23:287–293.
- Barbui T, Masciulli A, Ghirardi A, et al. ACE inhibitors and cytoreductive therapy in polycythemia vera. Blood. 2017;129:1226–1227.
- Taddei S. RAS inhibitors’ dose-dependent efficacy: myth or reality? Curr Med Res Opin. 2015;31:1245–1256.